Gold nanoparticles and cancer: Detection, diagnosis and therapy

Gold nanoparticles (AuNPS) represent one of the most studied classes of nanomaterials for biomedical applications, especially in the field of cancer research. In fact, due to their unique properties and high versatility, they can be exploited under all aspects connected to cancer management, from ea...

Full description

Saved in:
Bibliographic Details
Published in:Seminars in cancer biology 2021-11, Vol.76, p.27-37
Main Authors: Medici, Serenella, Peana, Massimiliano, Coradduzza, Donatella, Zoroddu, Maria Antonietta
Format: Article
Language:English
Subjects:
Animals
AuNPs
Cancer
Detection
Diagnosis
Gold
Gold nanoparticles
Humans
Metal Nanoparticles
Neoplasms - diagnosis
Neoplasms - therapy
Theranostic Nanomedicine - methods
Theranostic Nanomedicine - trends
Therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Gold nanoparticles (AuNPS) represent one of the most studied classes of nanomaterials for biomedical applications, especially in the field of cancer research. In fact, due to their unique properties and high versatility, they can be exploited under all aspects connected to cancer management, from early detection to diagnosis and treatment. AuNPs have thus been tested with amazing results as biosensors, contrast agents, therapeutics. Their importance as potent theranostics is undoubted, but the translation to clinical practice has been hampered by a series of aspects, such as the unclear toxicity in humans and the lack of thorough studies on reliable animal models. Still, their potential action is so appealing and the results so impressive that an outstanding number of papers is being published every year, with the consequence that any review on this topic becomes obsolete within a few months. Here we would like to report the latest findings on AuNPs research addressing all their functions as theranostic agents.
ISSN:1044-579X
1096-3650
DOI:10.1016/j.semcancer.2021.06.017